Log In
BCIQ
Print this Print this
 

ZW33

  Manage Alerts
Collapse Summary General Information
Company Zymeworks Inc.
DescriptionBispecific antibody targeting two epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu) protein epitopes linked to a cytotoxic payload
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody-drug conjugate; Bispecific antibody
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsBreast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/22/2016

Undisclosed

0

0

Get a free BioCentury trial today